Join Growin Stock Community!

世基生醫7595.TW Overview

TW StockBiotech. & Medical
(No presentation for 7595)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

世基生醫（7595）Overall Performance

世基生醫（7595）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

世基生醫（7595） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

世基生醫（7595）Key Information

世基生醫（7595）Profile

Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers molecular diagnostics to test adverse drug reactions; and DNA extraction products for gene expression analysis, clinical molecular diagnosis, human identity testing, forensics, and biomedical research applications. The company also provides pharmacogenomics test, drug allergy test, and functional medicine test services. In addition, it distributes various genomics and genetics equipment and reagents; and provides professional consultation, training program, analysis software, and technical support solutions. Further, the company offers CDMO services. The company was founded in 1994 and is headquartered in Taipei, Taiwan.

世基生醫（7595）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.33
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.90
PB Ratio
1.69
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
32.56%
Net Margin
-60.86%
Revenue Growth (YoY)
7.42%
Profit Growth (YoY)
-1.01%
3-Year Revenue Growth
49.26%
3-Year Profit Growth
46.58%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.33
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.90
PB Ratio
1.69
Price-to-FCF
-
Gross Margin
32.56%
Net Margin
-60.86%
Revenue Growth (YoY)
7.42%
Profit Growth (YoY)
-1.01%
3-Year Revenue Growth
49.26%
3-Year Profit Growth
46.58%
default symbol

7595

世基生醫

10.40D

4.81%

(0.05)

  • When is 7595's latest earnings report released?

    The most recent financial report for 世基生醫 (7595) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 7595's short-term business performance and financial health. For the latest updates on 7595's earnings releases, visit this page regularly.

  • What is the operating profit of 7595?

    According to the latest financial report, 世基生醫 (7595) reported an Operating Profit of -29.07M with an Operating Margin of -36.03% this period, representing a growth of 37.75% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 7595's revenue growth?

    In the latest financial report, 世基生醫 (7595) announced revenue of 80.68M, with a Year-Over-Year growth rate of 68.23%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 7595 have?

    At the end of the period, 世基生醫 (7595) held Total Cash and Cash Equivalents of 35.02M, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 7595 go with three margins increasing?

    In the latest report, 世基生醫 (7595) did not achieve the “three margins increasing” benchmark, with a gross margin of 30.75%%, operating margin of -36.03%%, and net margin of -51.23%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 7595's profit trajectory and future growth potential.

  • Is 7595's EPS continuing to grow?

    According to the past four quarterly reports, 世基生醫 (7595)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.82. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 7595?

    世基生醫 (7595)'s Free Cash Flow (FCF) for the period is 56.68M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 245.19% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.